Literature DB >> 20807012

Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects.

Justin A Jacobson1, Laura Yanoso-Scholl, David G Reynolds, Tulin Dadali, Gino Bradica, Susan Bukata, Edward J Puzas, Michael J Zuscik, Randy Rosier, Regis J O'Keefe, Edward M Schwarz, Hani A Awad.   

Abstract

To investigate the efficacy of endocrine parathyroid hormone treatment on tissue-engineered bone regeneration, massive femoral defects in C57Bl/6 mice were reconstructed with either 100:0 or 85:15 poly-lactic acid (PLA)/beta-tricalcium phosphate (β-TCP) scaffolds (hereafter PLA or PLA/βTCP, respectively), which were fabricated with low porosity (<30%) to improve their structural rigidity. Experimental mice were treated starting at 1 week postop with daily subcutaneous injections of 40 μg/kg teriparatide until sacrifice at 9 weeks, whereas control mice underwent the same procedure but were injected with sterile saline. Bone regeneration was assessed longitudinally using planar X-ray and quantitative microcomputed tomography, and the reconstructed femurs were evaluated at 9 weeks either histologically or biomechanically to determine their torsional strength and rigidity. Teriparatide treatment increased bone volume and bone mineral content significantly at 6 weeks and led to enhanced trabeculated bone callus formation that appeared to surround and integrate with the scaffold, thereby establishing union by bridging bone regeneration across the segmental defect in 30% of the reconstructed femurs, regardless of the scaffold type. However, the bone volume and mineral content in the PLA reconstructed femurs treated with teriparatide was reduced at 9 weeks to control levels, but remained significantly increased in the PLA/βTCP scaffolds. Further, bridged teriparatide-treated femurs demonstrated a prototypical brittle bone torsion behavior, and were significantly stronger and stiffer than control specimens or treated specimens that failed to form bridging bone union. Taken together, these observations suggest that intermittent, systemic parathyroid hormone treatment can enhance bone regeneration in scaffold-reconstructed femoral defects, which can be further enhanced by mineralized (βTCP) particles within the scaffold.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807012      PMCID: PMC3028991          DOI: 10.1089/ten.TEA.2010.0115

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  47 in total

Review 1.  Accelerated fracture healing.

Authors:  J Edward Puzas; Jeff Houck; Susan V Bukata
Journal:  J Am Acad Orthop Surg       Date:  2006       Impact factor: 3.020

Review 2.  Bone tissue engineering by gene delivery.

Authors:  Michelle D Kofron; Cato T Laurencin
Journal:  Adv Drug Deliv Rev       Date:  2006-06-21       Impact factor: 15.470

Review 3.  Mechanisms of anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis; Andrea Giustina; John P Bilezikian
Journal:  N Engl J Med       Date:  2007-08-30       Impact factor: 91.245

4.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

5.  Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing.

Authors:  Tetsuro Nakazawa; Arata Nakajima; Koji Shiomi; Hideshige Moriya; Thomas A Einhorn; Masashi Yamazaki
Journal:  Bone       Date:  2005-09-06       Impact factor: 4.398

6.  Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study.

Authors:  Brian Perri; Martin Cooper; Carl Lauryssen; Neel Anand
Journal:  Spine J       Date:  2006-11-20       Impact factor: 4.166

7.  Parathyroid hormone hormone-related protein and the PTH receptor regulate angiogenesis of the skin.

Authors:  A Godwin Diamond; Ryan M Gonterman; Aileen L Anderson; Keshav Menon; Carlos D Offutt; Chad H Weaver; William M Philbrick; John Foley
Journal:  J Invest Dermatol       Date:  2006-05-04       Impact factor: 8.551

8.  Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys.

Authors:  Takeshi Manabe; Satoshi Mori; Tasuku Mashiba; Yoshio Kaji; Ken Iwata; Satoshi Komatsubara; Azusa Seki; Yong-Xin Sun; Tetsuji Yamamoto
Journal:  Bone       Date:  2007-02-02       Impact factor: 4.398

9.  Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alpha-tricalcium phosphate scaffold.

Authors:  Atsuhiro Saito; Yoshihisa Suzuki; Makoto Kitamura; Shin-Ichi Ogata; Yusuke Yoshihara; Shingo Masuda; Chikara Ohtsuki; Masao Tanihara
Journal:  J Biomed Mater Res A       Date:  2006-06-15       Impact factor: 4.396

10.  Micro-computed tomography prediction of biomechanical strength in murine structural bone grafts.

Authors:  David G Reynolds; Colleen Hock; Saad Shaikh; Justin Jacobson; Xinping Zhang; Paul T Rubery; Christopher A Beck; Regis J O'keefe; Amy L Lerner; Edward M Schwarz; Hani A Awad
Journal:  J Biomech       Date:  2007-05-23       Impact factor: 2.712

View more
  9 in total

Review 1.  A comprehensive review of mouse diaphyseal femur fracture models.

Authors:  Zachary J Gunderson; Zachery R Campbell; Todd O McKinley; Roman M Natoli; Melissa A Kacena
Journal:  Injury       Date:  2020-04-18       Impact factor: 2.586

Review 2.  A review of mouse critical size defect models in weight bearing bones.

Authors:  Jonathan S Harris; Thomas B Bemenderfer; Alexander R Wessel; Melissa A Kacena
Journal:  Bone       Date:  2013-02-14       Impact factor: 4.398

Review 3.  Endogenous tissue engineering: PTH therapy for skeletal repair.

Authors:  Masahiko Takahata; Hani A Awad; Regis J O'Keefe; Susan V Bukata; Edward M Schwarz
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 4.  Parathyroid hormone applications in the craniofacial skeleton.

Authors:  H L Chan; L K McCauley
Journal:  J Dent Res       Date:  2012-10-15       Impact factor: 6.116

5.  Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases.

Authors:  Y-K Lee; Y-C Ha; K-H Koo
Journal:  Osteoporos Int       Date:  2012-10-18       Impact factor: 4.507

Review 6.  Teriparatide for treating delayed union and nonunion: A systematic review.

Authors:  Anissa Feby Canintika; Ismail Hadisoebroto Dilogo
Journal:  J Clin Orthop Trauma       Date:  2019-11-05

7.  Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: A case report.

Authors:  Li Xiaofeng; Xu Daxia; Chen Yunzhen
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

8.  Single-dose local administration of teriparatide with a octacalcium phosphate collagen composite enhances bone regeneration in a rodent critical-sized calvarial defect.

Authors:  Fumihiko Kajii; Atsushi Iwai; Hidenori Tanaka; Keiko Matsui; Tadashi Kawai; Shinji Kamakura
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2017-09-18       Impact factor: 3.368

9.  Three-Dimensional Printing of a Hybrid Bioceramic and Biopolymer Porous Scaffold for Promoting Bone Regeneration Potential.

Authors:  Kuo-Sheng Hung; May-Show Chen; Wen-Chien Lan; Yung-Chieh Cho; Takashi Saito; Bai-Hung Huang; Hsin-Yu Tsai; Chia-Chien Hsieh; Keng-Liang Ou; Hung-Yang Lin
Journal:  Materials (Basel)       Date:  2022-03-07       Impact factor: 3.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.